Ardent Health Partners, Inc. (ARDT) Key Metrics
ARDT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.69B
- Enterprise value
- $3.04B
- P/E (TTM)
- 22.1
- Forward P/E
- 9.5
- PEG ratio
- —
- Price / sales
- 0.3
- Price / book
- 1.1
- EV / EBITDA
- 7.2
- Dividend yield
- —
- Beta
- 0.72
ARDT key metrics, 2015–2025
Fiscal year ended December 31, 2025 · U.S. dollarsARDT valuation Price multiples at each fiscal year-end price.
ARDT returns How much profit the business earns on the capital it uses.
ARDT per-share figures Results divided by the shares outstanding at year-end.
ARDT financial health Debt, liquidity and how easily interest is covered.
ARDT efficiency & capital use Working capital cycle and where the cash goes.
ARDT valuation history
ARDT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ARDT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ARDT cash returned to shareholders
ARDT price vs earnings per share
ARDT key metrics
2015–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $1.25B | $2.27B | — | — | — | — | — | — | — |
| Enterprise value | $2.80B | $3.99B | — | — | — | — | — | — | — |
| P/E ratio | 9.2 | 10.8 | — | — | — | — | — | — | — |
| Price / sales | 0.2 | 0.4 | — | — | — | — | — | — | — |
| Price / book | 0.7 | 2.0 | — | — | — | — | — | — | — |
| Price / free cash flow | 4.8 | 17.8 | — | — | — | — | — | — | — |
| Price / operating cash flow | 2.7 | 7.2 | — | — | — | — | — | — | — |
| EV / sales | 0.4 | 0.7 | — | — | — | — | — | — | — |
| EV / EBITDA | 5.6 | 6.9 | — | — | — | — | — | — | — |
| EV / free cash flow | 10.8 | 31.3 | — | — | — | — | — | — | — |
| Earnings yield | 10.9% | 9.3% | — | — | — | — | — | — | — |
| Free cash flow yield | 20.7% | 5.6% | — | — | — | — | — | — | — |
| Dividend yield | — | 0.0% | — | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.0% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $8.83 | $17.08 | — | — | — | — | — | — | — |
| Per share | |||||||||
| Revenue per share | $44.71 | $44.94 | $37.76 | $35.81 | $34.00 | $29.52 | $21.30 | $14.93 | $14.40 |
| Earnings per share | $0.96 | $1.58 | $0.35 | $1.32 | $1.08 | −$1.01 | −$0.25 | $0.10 | −$0.33 |
| Operating cash flow per share | $3.33 | $2.37 | $1.55 | −$0.27 | $1.03 | $1.13 | $0.85 | $0.61 | $0.85 |
| Free cash flow per share | $1.83 | $0.96 | $0.59 | −$1.32 | $0.06 | −$0.01 | −$0.01 | $0.03 | $0.28 |
| Cash per share | $5.02 | $4.19 | $3.05 | $3.18 | — | $0.42 | $0.51 | $0.66 | — |
| Book value per share | $11.92 | $8.52 | $4.68 | $4.46 | — | $2.35 | $2.68 | $1.89 | — |
| Tangible book value per share | $5.07 | $1.52 | −$1.75 | −$1.97 | — | −$4.03 | −$3.68 | −$0.35 | — |
| Dividends per share | — | $0.00 | $0.00 | $1.22 | $0.43 | — | — | — | $3.96 |
| Capex per share | $1.50 | $1.41 | $0.96 | $1.05 | $0.97 | $1.14 | $0.86 | $0.57 | $0.57 |
| Debt per share | $16.01 | $17.19 | $16.73 | $16.67 | — | $8.94 | $6.76 | $1.71 | — |
| Shares outstanding | 141.5M | 132.7M | 143.3M | 143.3M | 143.3M | 141.0M | 141.0M | 141.0M | 141.0M |
| Change in shares outstanding | +6.6% | −7.3% | 0.0% | 0.0% | +1.6% | 0.0% | 0.0% | 0.0% | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | 9.6% | 23.3% | 7.7% | 29.6% | — | −40.3% | −11.1% | 5.5% | — |
| Return on invested capital (ROIC) | 8.6% | 12.2% | 7.5% | 7.2% | — | 8.5% | 7.3% | 16.8% | — |
| Return on assets (ROA) | 2.7% | 4.2% | 1.0% | 3.9% | — | −5.6% | −2.1% | 1.3% | — |
| Return on tangible assets | 3.1% | 5.2% | 1.2% | 4.8% | — | −7.7% | −2.4% | 1.9% | — |
| Free cash flow margin | 4.1% | 2.1% | 1.6% | −3.7% | 0.2% | −0.0% | −0.1% | 0.2% | 1.9% |
| Income quality (OCF / net income) | 3.46 | 1.50 | 4.41 | −0.20 | 0.95 | — | — | 5.87 | — |
| Financial health | |||||||||
| Total debt | $2.26B | $2.28B | $2.40B | $2.39B | — | $1.26B | $952.7M | $240.4M | — |
| Cash & short-term investments | $709.6M | $556.8M | $437.6M | $456.1M | — | $59.7M | $72.0M | $92.6M | — |
| Net debt | $1.55B | $1.73B | $1.96B | $1.93B | — | $1.20B | $880.7M | $147.8M | — |
| Debt / equity | 1.34 | 2.02 | 3.57 | 3.74 | — | 3.80 | 2.52 | 0.90 | — |
| Debt / assets | 0.43 | 0.46 | 0.47 | 0.49 | — | 0.46 | 0.40 | 0.22 | — |
| Net debt / EBITDA | 3.13 | 3.00 | 5.60 | 3.63 | — | 4.89 | 3.81 | 1.03 | — |
| Current ratio | 1.97 | 1.94 | 1.63 | 1.74 | — | 1.38 | 1.45 | 1.44 | — |
| Quick ratio | 1.85 | 1.82 | 1.52 | 1.61 | — | 1.24 | 1.29 | 1.29 | — |
| Interest coverage | 5.9 | 6.2 | 3.5 | 2.6 | 4.7 | 1.4 | 1.7 | 3.1 | 2.0 |
| Working capital | $1.01B | $887.3M | $624.0M | $600.7M | — | $235.6M | $229.1M | $143.0M | — |
| Invested capital | $3.24B | $2.86B | $2.63B | $2.57B | — | $1.53B | $1.26B | $414.3M | — |
| Tangible asset value | $716.2M | $593.3M | $160.7M | $128.7M | — | −$188.0M | −$136.2M | $79.7M | — |
| Net current asset value | −$1.55B | −$1.60B | −$2.40B | −$2.40B | — | −$1.17B | −$877.8M | −$218.2M | — |
| Graham number | $16.05 | $17.43 | $6.08 | $11.50 | — | — | — | $2.10 | — |
| Graham net-net per share | −$16.41 | −$17.04 | −$20.53 | −$19.83 | — | −$10.89 | −$8.23 | −$2.68 | — |
| Capital allocation | |||||||||
| Dividends paid | — | $0 | $0 | $174.8M | $62.1M | — | — | — | $558.6M |
| Dividend payout ratio | — | 0.0% | 0.0% | 92.5% | 40.3% | — | — | — | — |
| Dividends + buybacks / free cash flow | — | 0.0% | 0.0% | — | 785.8% | — | — | — | — |
| Capex / revenue | 3.4% | 3.1% | 2.5% | 2.9% | 2.9% | 3.9% | 4.0% | 3.8% | 4.0% |
| Capex / operating cash flow | 45.0% | 59.5% | 62.0% | — | 94.6% | 100.7% | 101.7% | 93.9% | 67.2% |
| Capex / depreciation | 1.36 | 1.28 | 0.98 | 1.09 | 1.01 | 1.12 | 1.11 | 1.13 | 0.90 |
| Stock-based compensation / revenue | 0.6% | 0.3% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| R&D / revenue | — | — | — | — | — | 0.4% | 0.7% | — | — |
| SG&A / revenue | 18.9% | 65.1% | 67.0% | 65.7% | 64.3% | 64.3% | 38.9% | 92.6% | 15.6% |
| Efficiency | |||||||||
| Days sales outstanding | 41.2 | 46.8 | 47.2 | 43.5 | — | 43.1 | 43.5 | 45.3 | — |
| Days of inventory on hand | 273.9 | 39.0 | 275.5 | 40.9 | — | — | — | — | — |
| Days payables outstanding | 1,007.1 | 154.7 | 1,030.6 | 122.6 | — | — | — | — | — |
| Cash conversion cycle (days) | -691.9 | -69.0 | -707.9 | -38.1 | — | — | — | — | — |
| Receivables turnover | 8.85 | 7.80 | 7.74 | 8.38 | — | 8.47 | 8.40 | 8.06 | — |
| Payables turnover | 0.36 | 2.36 | 0.35 | 2.98 | — | 0.00 | 0.00 | 0.00 | — |
| Inventory turnover | 1.33 | 9.37 | 1.32 | 8.91 | — | 0.00 | 0.00 | 0.00 | — |
| Asset turnover | 1.23 | 1.19 | 1.09 | 1.06 | — | 1.63 | 1.74 | 1.94 | — |
| Average receivables | $714.6M | $764.4M | $698.9M | $612.0M | — | $491.5M | $357.4M | $261.0M | — |
| Average payables | $429.6M | $437.9M | $397.7M | $320.8M | — | $228.4M | $179.2M | $131.9M | — |
| Average inventory | $116.8M | $110.3M | $106.3M | $107.2M | — | $84.5M | $65.6M | $47.1M | — |
| Intangibles / total assets | 18.3% | 18.7% | 18.1% | 19.0% | — | 32.8% | 37.8% | 29.1% | — |
Computed from ARDT's annual financial statements (latest annual report filed March 16, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ARDT valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Ardent Health Partners traded at 9.2 times earnings. Based on the latest twelve months, the trailing P/E is 22.1 and the forward P/E is 9.5. Ardent Health Partners earned a return on equity of 9.6% and a return on invested capital of 8.6% in fiscal 2025. It ended the year with $2.3 billion of debt and $709.6 million in cash and short-term investments, net debt of $1.6 billion.
See the ARDT income statement, the ARDT chart for price history, or the ARDT stock overview for the latest quote and news.
ARDT key metrics FAQ
What is Ardent Health Partners's P/E ratio?
Ardent Health Partners's trailing P/E ratio is 22.1 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 9.5. At the end of fiscal 2025 it was 9.2.
What is Ardent Health Partners's EV/EBITDA?
Ardent Health Partners's enterprise value was 5.6 times EBITDA at the end of fiscal 2025 (enterprise value $2.8 billion, EBITDA $497.3 million); the current EV/EBITDA is 7.2.
What is Ardent Health Partners's return on equity?
Ardent Health Partners's return on equity (ROE) was 9.6% in fiscal 2025: net income of $135.8 million on average shareholders' equity of $1.4 billion.
What is Ardent Health Partners's ROIC?
Ardent Health Partners's return on invested capital was 8.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Ardent Health Partners have?
Ardent Health Partners had total debt of $2.3 billion at the end of fiscal 2025, a debt-to-equity ratio of 1.34 and $1.6 billion of net debt (3.13 times EBITDA).
What is Ardent Health Partners's free cash flow yield?
Ardent Health Partners generated $258.6 million of free cash flow in fiscal 2025, a free cash flow yield of 20.7% on its market value at year-end ($1.2 billion).
What is Ardent Health Partners's current ratio?
Ardent Health Partners's current ratio was 1.97 at the end of fiscal 2025: current assets were 1.97 times current liabilities.